IGL represents the Danish generics and biosimilar companies in Medicines for Europe and is a Member of the Board. Medicines for Europe represents the generic, biosimilar and value added industries and aim to increase the health and wellbeing of all Europeans through better access to high quality medicines.
Together, the member companies of Medicines for Europe are making a very significant direct contribution to the European economy through 350 European manufacturing sites and more than 160,000 people employed in high-quality technology jobs. Without generic and biosimilar medicines European healthcare providers would have had to pay an additional €100 billion for medicines in 2014.
For more information read here (in Danish) or see www.medicinesforeurope.com